More info
First-in-class TAK1-MKK3 protein-protein interaction (PPI) inhibitor for the treatment of ulcerative colitis through modulating TNF-α production, suppressing the TAK1/MKK3/p38/MnK1/MK2/elF4E signal pathways through binding with MKK3 and disrupting the TAK1 phosphorylating MKK3